Intravenous immunoglobulin in neurological disorders: a mechanistic perspective

被引：21
作者：
Misra, N
Bayry, J
Ephrem, A
Dasgupta, S
Delignat, S
Van Huyen, JPD
Prost, F
Lacroix-Desmazes, S
Nicoletti, A
Kazatchkine, MD
Kaveri, SV
机构：
[1] Inst Biomed Cordeliers, INSERM, U681, F-75006 Paris, France
[2] Univ Paris 06, Inst Biomed Cordeliers, Paris, France
来源：
JOURNAL OF NEUROLOGY | 2005年 / 252卷 / Suppl 1期
关键词：
intravenous immunoglobulin; neurological disorders; mechanisms;
D O I：
10.1007/s00415-005-1102-7
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over 25 years. It is a safe preparation with no long-term side effects. IVIg was first demonstrated to be effective in autoimmune disorders, two decades ago, in the treatment of acute immune thrombocytopenia. Since then, the therapeutic efficacy of IVIg has been established in Guillain Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis (MG), dermatomyositis (DM), Kawasaki syndrome and the prevention of graft-versus-host disease in recipients of allogeneic bone marrow transplants and reported in a large number of other autoimmune and systemic inflammatory conditions.
引用
收藏
页码：1 / 6
页数：6
相关论文
共 53 条
  • [1] Intravenous immunoglobulin treatment in multiple sclerosis - Effect on relapses
    Achiron, A
    Gabbay, U
    Gilad, R
    Hassin-Baer, S
    Barak, Y
    Gornish, M
    Elizur, A
    Goldhammer, Y
    Sarova-Pinhas, I
    [J]. NEUROLOGY, 1998, 50 (02) : 398 - 402
  • [2] Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes macrophages
    Andersson, J
    SkansenSaphir, U
    Sparrelid, E
    Andersson, U
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 104 : 10 - 20
  • [3] POOLED HUMAN-IGG MODULATES CYTOKINE PRODUCTION IN LYMPHOCYTES AND MONOCYTES
    ANDERSSON, U
    BJORK, L
    SKANSENSAPHIR, U
    ANDERSSON, J
    [J]. IMMUNOLOGICAL REVIEWS, 1994, 139 : 21 - 42
  • [4] ANDERSSON UG, 1993, IMMUNOLOGY, V79, P211
  • [5] Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases
    Ballow, M
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 100 (02) : 151 - 157
  • [6] BASTA M, 1991, BLOOD, V77, P376
  • [7] F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins:: a novel effector function of immunoglobulins
    Basta, M
    Van Goor, F
    Luccioli, S
    Billings, EM
    Vortmeyer, AO
    Baranyi, L
    Szebeni, J
    Alving, CR
    Carroll, MC
    Berkower, I
    Stojilkovic, SS
    Metcalfe, DD
    [J]. NATURE MEDICINE, 2003, 9 (04) : 431 - 438
  • [8] HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN EXERTS ITS BENEFICIAL EFFECT IN PATIENTS WITH DERMATOMYOSITIS BY BLOCKING ENDOMYSIAL DEPOSITION OF ACTIVATED COMPLEMENT FRAGMENTS
    BASTA, M
    DALAKAS, MC
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (05) : 1729 - 1735
  • [9] Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-α present in serum from patients with systemic lupus erythematosus
    Bayry, J
    Lacroix-Desmazes, S
    Delignat, S
    Mouthon, L
    Weill, B
    Kazatchkine, MD
    Kaveri, SV
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (12): : 3497 - 3502
  • [10] Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?
    Bayry, J
    Lacroix-Desmazes, S
    Kazatchkine, MD
    Kaveri, SV
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (06) : 306 - 310
123456